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1Background and Purpose—Sustained successful reperfusion is an important prognostic factor for good clinical outcome 
in acute ischemic stroke. We aimed to identify the prevalence, clinical impact, and predictors of early reocclusion after 
initially successful thrombectomies within a prospective cohort.
Methods—A total of 711 stroke patients with successful reperfusion (modified Thrombolysis in Cerebral Infarction, 2b/3) 
followed with magnetic resonance or computed tomographic angiography at 24 to 48 hours were included. Multivariable 
logistic regression analysis was used to evaluate associated factors and clinical impact. Results are displayed as adjusted 
odds ratio (aOR) and 95% CI. Improvement in accuracy of additional imaging findings on angiography control runs after 
the intervention was evaluated by area under the curve.
Results—Early reocclusion was observed in 16 of 711 successfully reperfused patients (2.3%; 95% CI: 1.1–3.3; median 
delay: 20 hours). Suggestive predictors were higher platelets on admission (aOR, 1.01; 95% CI: 1.01–1.02), prestroke 
functional dependence (aOR, 7.12; 95% CI: 1.49–34.03), and stroke of undetermined or other specified pathogenesis 
in the TOAST classification (aOR, 7.19; 95% CI: 1.10–47.05 and aOR, 36.50; 95% CI: 4.47–298.11, respectively). 
When implementing residual embolic fragments or stenosis at the thrombectomy site into the logistic regression model, 
discrimination between patients with and without reocclusion improved significantly (area under the curve, 0.955 versus 
0.854; P=0.023). Early reocclusion was an independent predictor of unfavorable outcome at 90 days (aOR for modified 
Rankin Scale ≤2, 0.13; 95% CI: 0.03–0.57).
Conclusions—Early reocclusion within 48 hours after successful mechanical thrombectomy is rare but associated with poor 
outcome. Patients with high platelets on admission and residual embolic fragments or stenosis at the thrombectomy site 
are at high risk for reocclusion, which may be prevented or corrected after carefully re-evaluating the past angiographic 
run.   (Stroke. 2018;49:00-00. DOI: 10.1161/STROKEAHA.118.021685.)
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Landmark randomized trials established mechanical endo-vascular thrombectomy as the most effective reperfusion 
therapy for patients with acute ischemic stroke presenting 
with large vessel occlusions.1–7 However, despite successful 
recanalization, reocclusion of the target vessel occurs in 3% 
to 9% of patients.8–10 Because rapid, sustained, and complete 
reperfusion is the most important modifiable prognostic fac-
tor for a favorable clinical outcome,11 we aimed to identify 
the prevalence and predictors of early reocclusion within 48 
hours after an initially successful endovascular thrombectomy 
within a prospective cohort of consecutive patients with acute 
ischemic stroke from a single center.
Methods
Study Cohort
This article adheres to the American Heart Association Journals’ 
implementation of the Transparency and Openness Promotion 
Guidelines (available online at http://www.ahajournals.org/content/
TOP-guidelines). The data that support the findings of this study are 
available from the corresponding author on reasonable request. All 
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patients with acute ischemic stroke (n=972) treated by mechanical 
thrombectomy between January 2010 and July 2017 with a Solitaire 
stent retriever (Medtronic, Dublin, Ireland)±distal aspiration catheters 
(SOFIA, Microvention, Tustin, CA; Catalyst, Stryker, Cork, Ireland; 
ACE, Penumbra, Alameda, CA) were reviewed. The final study pop-
ulation consisted of patients successfully treated with thrombectomy 
(n=809), defined as modified Thrombolysis in Cerebral Infarction 
(mTICI) score 2b or 3,12 with magnetic resonance angiography 
or computed tomographic angiography imaging available at fol-
low-up within 48 hours (n=711; Figure 1 for study flow chart). The 
reviewed patient cohort was extracted from the prospective institu-
tional Bernese Stroke Registry. Ethical committee approval for this 
retrospective analysis was obtained (Kantonale Ethikkommission für 
die Forschung Bern, Bern, Switzerland, amendment access number: 
231/2014). The prospective registry database contains patient base-
line characteristics, risk factors profile, time metrics, and clinical fol-
low-up data, including a standardized 3-month clinical visit, which 
was available for 666 of 711 patients (93.7%).
Secondary Prevention and 
Postinterventional Medication
Deep vein prophylaxis and start of secondary prevention were per-
formed according to institutional Standard Operating Procedures (see 
excerpt from the Standard Operating Procedure depicted in Data I 
in the online-only Data Supplement). In short, in case of bridging 
or additional administration of intra-arterial urokinase during the in-
terventional procedure, prophylaxis of deep vein thrombosis using 
low molecular weight heparin was started after exclusion of cerebral 
hemorrhage on 24-hour follow-up imaging. After mechanical throm-
bectomy without intravenous thrombolysis or intra-arterial urokinase, 
low molecular weight heparin was started immediately after the in-
tervention. Type and initiation of secondary prevention (oral anti-
coagulants or antithrombotic treatment) depended on the presumed 
pathogenesis, treatment modality, and infarct size. In case of unde-
termined pathogenesis and mechanical thrombectomy only (without 
intravenous thrombolysis or intra-arterial Urokinase), a loading dose 
of 250 mg aspirin was administered directly after the procedure fol-
lowed by 100 mg aspirin or 75 mg clopidogrel daily. After bridging or 
additional administration of intra-arterial urokinase, antithrombotic 
treatment was started only if 24-hour follow-up ruled out intracere-
bral hemorrhage. In case of imminent space-occupying brain edema 
and if a potential hemicraniectomy was considered, administration 
of platelets was withheld. In cases of nonvalvular atrial fibrillation, 
direct oral anticoagulant treatment was started after 3 to 12 days 
depending on the size of the infarct (see Data I in the online-only 
Data Supplement for details). No intermediate antiplatelet therapy 
until the start of the direct oral anticoagulant treatment was adminis-
tered. In cases of highly embolic source of embolism (eg, mechanical 
heart valve), immediate initiation of a therapeutic heparinization was 
considered. When large artery-to-artery embolism was considered, 
the presumed cause and the degree of cervical stenosis were >50%, 
and acute stenting or CEA was routinely performed. In case of acute 
stenting, a loading dose of 250 to 500 mg aspirin (during the proce-
dure) was administered followed by daily 100 mg aspiring and 75 
mg clopidogrel. In cases of CEA, 100 mg aspirin was administered 
daily. Transient therapeutic heparinization with low molecular weight 
heparin was used for transient bridging until CEA in some cases. In 
cases of <50% cervical stenosis, an individual decision was made. 
In addition, all cases with presumed large artery-to-artery embolism 
were treated with a high-dose statin (eg, 80 mg atorvastatin) from the 
index day on. For other pathogeneses and special cases, please see 
Data I in the online-only Data Supplement for further details on the 
type and start of secondary prevention.
Image Analysis
The following variables were evaluated: occlusion site (intracranial 
ICA/carotid-T/L versus M1 versus M2/M3/ACA versus posterior 
circulation), tandem occlusion (defined as cervical occlusion/90% 
stenosis and intracranial occlusion), number of clot retrieval maneu-
vers, use of balloon-guide catheter and distal access aspiration cath-
eter, intra- or extracranial stenting, and final mTICI score. Iatrogenic 
emboli in previously unaffected territories were not considered as 
reocclusions. The final mTICI score and complete set of angiographic 
images were operator reported and reviewed by a second independent 
neuroradiologist (P.J.M.) not directly involved in the intervention. In 
an occlusion, site-matched analysis (5:1 random matching of the con-
trol group, see Statistical Analysis section), the presence of residual 
nonoccluding thrombus fragments or vessel wall irregularities/ste-
nosis on final angiographic control runs (excluding obvious material-
induced vasospasm) was further analyzed by 2 independent observers 
(P.J.M. and J.K.; Figures I and II in the online-only Data Supplement 
for exemplary cases).
Statistical Analysis
Univariate comparison was performed by Fischer exact test for cat-
egorical variables. Mann-Whitney U test was used for non-normally 
distributed continuous and ordinally scaled variables and Welsch t 
test for normally distributed variables. Variables with P<0.2 in uni-
variate comparison entered a backward likelihood ratio multivariable 
binary logistic regression model. Output of the logistic regression 
model is displayed as adjusted odds ratios (aOR) and corresponding 
95% CI. In a second step, analyses were rerun in an occlusion site-
matched cohort (5:1 univariate random matching) implementing the 
variable nonoccluding thrombus fragments or vessel wall irregulari-
ties into the model. Incremental value of this imaging variable on 
accuracy of the model was evaluated using receiver operator char-
acteristics analysis with area under the curve (AUC) calculation and 
Figure 1. Study flow chart. Study flow chart of 
included patients and respective exclusion cri-
teria. LVO indicates large vessel occlusions; and 
TICI, Thrombolysis in Cerebral Infarction.
D
ow
nloaded from
 http://ahajournals.org by on September 18, 2018
Mosimann et al  Early Reocclusion After Successful Thrombectomy  3
AUC comparison according to Delong.2 Furthermore, integrated 
discrimination improvement and net reclassification improvement 
3
 after versus before implementation of the variable nonoccluding 
thrombus fragments or vessel wall irregularities were evaluated. To 
determine the clinical impact of early reocclusion, early reocclusion 
was entered as a variable in a multivariable binary logistic regression 
term together with potential clinical confounders, including age, sex, 
National Institutes of Health Stroke Scale on admission, indepen-
dence prior the stroke, TICI3 versus TICI2b, bridging IVT, time to 
admission, initial ASPECTS, and site of occlusion. Receiver oper-
ating characteristic analysis and AUC comparison were performed 
in R (R: A language and environment for statistical computing, R 
Foundation for Statistical Computing, Vienna, Austria) using the R 
package pROC.4 Calculation of integrated discrimination improve-
ment and net reclassification improvement was performed with the 
R package Hmisc. All other statistical analyses were performed with 
SPSS version 25 (IBM, Armonk, NY).
Results
Prevalence of Early Reocclusion
Early reocclusion was observed in 16 of 711 patients in whom 
an mTICI 2b/3 result had been obtained on the past angio-
graphic run (2.3%; 95% CI: 1.1%–3.3%). A detailed descrip-
tion of the 16 patients with early reocclusion can be found 
in Table I in the online-only Data Supplement. Median time 
interval to the diagnosis of early reocclusion was 20 hours 
after imaging on admission (interquartile range, 15–24 hours). 
Most reocclusions were associated with a lack of clinical im-
provement (n=3) after intervention or secondary worsening as 
evidenced by a drop in National Institutes of Health Stroke 
Scale (n=11; Table I in the online-only Data Supplement). 
Silent or asymptomatic occlusions were observed in 2 patients 
with excellent collaterals. Repeated thrombectomy for early 
reocclusion was performed in 3 of 16 patients (18.8%) only. 
Reasons for withholding repeated endovascular thrombec-
tomy were extensive infarction in the reoccluded territory 
without any relevant residual perfusion mismatch (n=8), se-
vere blood-brain barrier breakdown with early hemorrhagic 
transformation (n=1), a presumed benign course because 
of excellent collaterals (n=2), or further distal clot location 
within the same M2 segment (n=2).
Baseline Factors and Imaging Characteristics 
Associated With Early Reocclusion
A comparison of patients with and without reocclusion (n=16 
and 695, respectively) is provided in Table 1. Patients with 
early reocclusion had significantly higher platelet counts on 
admission (265 versus 216 g/L; P=0.001), higher frequencies 
of stroke of undetermined (50.0% versus 39.0%), and other 
specified (31.3% versus 5.9%) pathogenesis in the TOAST 
classification (P=0.002) and M2/M3/A1 as the initial occlu-
sion site (37.5% versus 10.1%; P=0.020). There were no dif-
ferences in the rate of cervical artery dissection (6.6% versus 
3.3%; P=0.427), tandem occlusion (6.3% versus 13.7%; 
P=0.710), or interventional characteristics, including use of 
a balloon-guiding catheter (68.6% versus 70.0%; P>0.999), 
distal aspiration catheter (50.0% versus 43.9%; P=0.622), 
number of passes or retrievals (median 1 versus 1; P=0.462), 
and frequency of extracranial stenting (6.3% versus 12.4%; 
P=0.708). In multivariable logistic regression analysis, 
functional dependency before the stroke, site of occlusion, 
stroke pathogenesis, and admission platelet count were fac-
tors significantly associated with early reocclusion within 48 
hours (Table 2). Univariate receiver operating characteristic 
analyses revealed an AUC of 0.734, 95% CI: 0.614 to 0.855 
for platelet count with early reocclusion set as dependent vari-
able (Figure III in the online-only Data Supplement). The best 
cutoff between early and no reocclusion was a platelet count 
of ≥220 g/L (Youden index), yielding a sensitivity of 87.5% 
and specificity of 46.9%.
Thirteen of 16 (81.3%) patients with reocclusion had an-
giographic irregularities on the past angiographic run, which 
were not reported or misinterpreted by the neurointerven-
tionalist as material-induced vasospasm. In an occlusion site-
matched cohort (n=96; 16 reocclusion patients, 80 occlusion 
site-matched nonreocclusion patients), univariate comparison 
revealed comparable differences (see Table 3). Admission 
platelet count (aOR for every g/L increase, 1.01; 95% CI: 
1.00–1.03; P=0.042), residual thrombus/vessel wall irregular-
ities after thrombectomy (aOR, 58.94; 95% CI: 4.94–703.16; 
P=0.001), and other determined pathogenesis according to 
the TOAST classification (aOR, 43.10; 95% CI: 1.99–935.00; 
P=0.017) were the only significant predictors of early reocclu-
sion in a multivariable logistic regression analysis in this sub-
group (Table 4). The receiver operating characteristic curve 
of the predicted probability output of the logistic regression 
model, including factors in Table 4, is shown in Figure 2A 
(AUC, 0.955; 95% CI: 0.916–0.994). This AUC was signif-
icantly higher than the prediction derived from the same lo-
gistic regression model without the term residual thrombus/
vessel wall irregularities after thrombectomy (Figure 2B; 
new AUC: 0.854; 95% CI: 0.757–0.952, DeLong test for 
testing the difference of AUC not equal to 0: P=0.028), sug-
gesting an important added value of this imaging variable. 
Correspondingly, the integrated discrimination improvement 
was 0.27 (95% CI: 0.14–0.40; P<0.001) with a net reclassi-
fication improvement of 1.27 (95% CI: 0.85–1.59; P<0.001), 
suggesting improvement in a corrected classification.
Because 98 of 809 patients (12%) were excluded from 
the study because of absent computed tomographic angiog-
raphy or magnetic resonance angiography on early follow-up 
imaging, despite our institutional policy, we conducted a sen-
sitivity analysis to compare their baseline characteristics and 
outcome variables with the included patients (see Table II in 
the online-only Data Supplement for details). On average, 
patients without arterial imaging were 4 years older, had 4× 
more sICH, twice the mortality rate, and twice as less good 
functional outcomes at 90 days.
Clinical Outcome
Patients with early reocclusion compared with those with 
sustained recanalization had a worse clinical outcome at 
day 90 (modified Rankin Scale ≤2, 20.0% versus 51.3%; 
P=0.019) although mortality did not differ (20.0% versus 
19.0%; P>0.999). The 3 patients with early reocclusion in 
whom thrombectomy was repeated showed no clinical im-
provement. Early reocclusion was an independent predic-
tive factor related to lower rates of functional independence 
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Table 1. Baseline Characteristics
 
All Patients With Available 48-
Hour Follow-Up Intracranial 
Vessel Imaging (n=711)
Early (<48 Hours) Reocclusion 
(n=16)
No Early Reocclusion 
(n=695) P Value
Age 70.2±14.9 73.3±13.0 70.2±15.0 0.354
Sex, female 49.1% (349/711) 68.8% (11/16) 48.6% (338/695) 0.133
Preadmission independence (mRS >2) 92.0% (652/709) 81.3% (13/16) 92.2% (639/693) 0.131
Secondary transferal 30.7% (218/710) 31.3% (5/16) 30.7% (213/694) >0.999
Admission NIHSS 15 (9–20; n=709) 10 (5–19; n=16) 15 (10–20; n=693) 0.070
Risk factors
  Hypertension 70.4% (499/709) 81.3% (13/16) 70.1% (486/693) 0.417
  Hyperlipidemia 59.6% (412/706) 56.3% (9/16) 59.7% (412/690) 0.801
  Smoking 29.3% (206/704) 31.3% (5/16) 29.2% (201/688) 0.789
  Previous CVE 12.3% (87/709) 6.3% (1/16) 12.4% (86/693) 0.708
  CAD 20.3% (143/705) 0% (0/15) 20.7% (143/690) 0.050
Medication
  Antiplatelet (dual, aspirin, none)    0.845
   Dual 2.0% (14/708) 0% (0/16) 2.0% (14/692)  
   Aspirin 30.6% (217/708) 25.0% (4/16) 30.8% (213/692)  
   None 67.4% (477/708) 75.0% (12/16) 67.2% (465/692)  
  Anticoagulation    0.489
   OAC 9.0% (64/708) 0% (0/16) 9.2% (64/692)  
   NOAC 4.7% (33/708) 0% (0/16) 4.8% (33/692)  
   None 86.3% (611/708) 100% (16/16) 86.0% (595/692)  
  Statin 26.9% (190/706) 25.0% (4/16) 27.0% (186/690) >0.999
Systolic blood pressure, mm Hg 153 (133–171; n=672) 162 (130–182; n=16) 152 (133–171; n=656) 0.369
Diastolic blood pressure, mm Hg 81 (71–94; n=673) 79 (71–105; n=16) 81 (71–94; n=657) 0.952
Admission glucose, mmol/L 6.7 (5.8–7.9; n=685) 6.8 (5.7–8.4; n=15) 6.7 (5.8–7.9; n=670) 0.850
Admission INR 1.0 (1.0–1.1; n=702) 1.0 (1.0–1.1; n=16) 1.0 (1.0–1.1; n=686) 0.216
Admission platelet count 218 (176–260; n=705) 265 (227–392; n=16) 216 (175–259; n=689) 0.001*
TOAST    0.002*
  Large‐artery atherosclerosis 10.7% (76/711) 0% (0) 10.9% (76/695)  
  Cardioembolic 43.6% (310/711) 18.8% (3/16) 44.2% (307/695)  
  Other pathogenesis 6.5% (46/711) 31.3% (5/16) 5.9% (41/695)  
  Unknown pathogenesis 39.2% (279/711) 50.0% (8/16) 39.0% (271/695)  
Symptom-onset to admission (witnessed 
symptom onset only, min)
102 (65–180; n=464) 106 (77–163; n=9) 101 (65–180; n=455) 0.881
Symptom-onset to admission (including last-
seen-well, min)
142 (75–249; n=684) 162 (101–307; n=15) 141 (75–248; n=669) 0.370
Initial modality for imaging diagnosis    0.804
  CT 47.8% (339/709) 43.8% (7/16) 47.9% (332/693)  
  MRI 52.2% (370/790) 56.3% (9/16) 52.1% (361/693)  
Intravenous tPA bridging 42.3% (301/711) 31.3% (5/16) 42.6% (296/695) 0.448
Intracranial occlusion site    0.020†
  Intracranial ICA or carotid T 23.1% (164/711) 12.5% (2/16) 23.3% (162/695)  
(Continued )
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at day 90 after adjusting for age, sex, admission National 
Institutes of Health Stroke Scale, prestroke independence, 
TICI3 versus TICI2b, bridging IVT, time to admission, ad-
mission ASPECTS, and site of occlusion (aOR, 0.13; 95% 
CI: 0.03–0.57; P=0.007).
Discussion
In our cohort of 711 patients with available computed to-
mographic angiography or magnetic resonance angiog-
raphy follow-up imaging, we identified 4 factors associated 
with early reocclusion despite an initial mTICI2b/3 result: 
elevated platelet counts at admission >220 g/L, missed re-
sidual thrombus or stenosis on the past angiographic run after 
thrombectomy, M2 occlusion as the initial occlusion site, 
and stroke of undetermined cause. Reports on early reocclu-
sion in the era of modern endovascular treatment are scarce. 
According to our results, unexpected early reocclusion within 
48 hours after successful mechanical thrombectomy occurs 
in 2.3% of cases, which compares favorably to the 3% to 4% 
reocclusion rate within 24 hours after successful intravenous 
or intra-arterial thrombolysis.13–15 In a post hoc analysis of the 
REVASCAT study assessing 24-hour revascularization rates 
after stent retriever therapy,8 the authors observed 2 early 
reocclusions of 63 mTICI2b/3 patients (3.1%) for all occlu-
sion sites, except M2. In our cohort, however, M2 location 
was a statistically significant predictor of early reocclusion 
in univariate analysis. Given a 10-fold larger sample size in 
our study, which appears to be the largest so far, we think that 
limited statistical power in the REVASCAT subgroup anal-
ysis may explain this difference.
Residual atherosclerotic, stenosis of a pre-existing lesion 
at the target site can lead to immediate or delayed occlusion 
in 25% of cases.16 Only one of our patients presented with 
early reocclusion because of an underlying atherosclerotic 
stenosis that had been missed, underlying the importance of 
repeating an angiographic run after corrective measures to 
  M1 57.5% (409/711) 43.8% (7/16) 57.8% (402/695)  
  M2/M3/A1 10.7% (76/711) 37.5% (6/16) 10.1% (70/695)  
  Posterior circulation 8.7% (62/711) 6.3% (1/16) 8.8% (61/695)  
Tandem occlusion (cervical occlusion or >90% 
stenosis)
13.5% (96/710) 6.3% (1/16) 13.7% (95/694) 0.710
Underlying cervical dissection (on admission) 3.4% (24/709) 6.3% (1/16) 3.3% (23/693) 0.427
Intervention
  General anesthesia 68.5% (486/710) 56.3% (9/16) 68.7% (477/694) 0.288
  No. of maneuvers 1 (1–2) 1 (1–4) 1 (1–2) 0.462
  Time from groin to TICI2b (min) 38 (27–59) 43 (29–59) 38 (27–59) 0.423
  BGC 70.0% (497/710) 68.8% (11/16) 70.0% (486/694) >0.999
  Distal aspiration catheter 44.0% (313/711) 50.0% (8/16) 43.9% (305/695) 0.622
  Intracranial stenting 2.8% (20/709) 0% (0/16) 2.9% (20/693) >0.999
  Extracranial stenting 12.3% (87/710) 6.3% (1/16) 12.4% (86/694) 0.708
  TICI3 56.5% (402/711) 56.3% (9/16) 56.5% (393/695) >0.999
Dual antiplatelet medication refers to aspirin+another antiplatelet drug (clopidogrel, prasugrel, etc). BGC indicates balloon-guiding catheter; CAD, coronary artery 
disease; CT, computed tomography; CVE, cerebrovascular event; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIHSS, National Institutes of Health 
Stroke Scale; NOAC, novel oral anticoagulant (rivaroxaban, apixaban, etc); OAC, oral anticoagulant (coumarins); TICI, Thrombolysis in Cerebral Infarction; and tPA, 
tissue-type plasminogen activator.
*P<0.01, †P<0.05.
Table 1. Continued
 
All Patients With Available 48-
Hour Follow-Up Intracranial 
Vessel Imaging (n=711)
Early (<48 Hours) Reocclusion 
(n=16)
No Early Reocclusion 
(n=695) P Value
Table 2. Logistic Regression With P<0.2 in Univariate Comparison
Variable Adjusted OR 95% CI P Value
TOAST (indicator: cardioembolic)   0.007*
  Large‐artery atherosclerosis Did not converge
  Unknown pathogenesis 7.19 1.10–47.05 0.039†
  Other pathogenesis 36.50 4.47–298.1 0.001*
Admission platelets 1.01 1.01–1.02 <0.001*
Sex Variable excluded from model
Prestroke independence 0.14 0.03–0.67 0.014†
Risk factor CAD Did not converge
Admission NIHSS Variable excluded from model
Site of occlusion (indicator: 
posterior circulation)
  0.007*
  Intracranial ICA or carotid T 0.67 0.05–8.93 0.764
  M1 1.20 0.13–11.63 0.873
  M2/M3/A1 9.35 0.91–96.10 0.060
n=698; Nagelkerkes R2: 0.386. CAD indicates coronary artery disease; 
NIHSS, National Institutes of Health Stroke Scale; and OR, odds ratio.
*P<0.01, †P<0.05.
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Table 3. Baseline Characteristics (Matched Cohort)
 
Early (<48 Hours)  
Reocclusion (n=16)
No Early Reocclusion  
(1:5 Matching, n=80) P Value
Age 73.3±13.0 72.1±14.8 0.743
Sex, female 68.8% (11/16) 42.5% (34/80) 0.098
Preadmission independence (mRS >2) 81.3% (13/16) 92.5% (74/80) 0.169
Secondary transferal 31.3% (5/16) 36.3% (29/80) 0.782
Admission NIHSS 10 (5–19; n=16) 14 (8–18; n=80) 0.251
Risk factors
  Hypertension 81.3% (13/16) 62.0% (49/80) 0.163
  Hyperlipidemia 56.3% (9/16) 64.6% (51/79) 0.577
  Smoking 31.3% (5/16) 26.6% (21/79) 0.761
  Previous CVE 6.3% (1/16) 8.8% (7/80) >0.999
  CAD 0% (0/15) 18.8% (15/80) 0.117
Medication
  Antiplatelet (dual, aspirin, none)   0.769
   Dual 0% (0/16)  0% (0/80)  
   Aspirin 25.0% (4/16) 32.5% (26/80)  
   None 75.0% (12/16) 67.5% (54/80)  
  Anticoagulation   0.283
   OAC 0% (0/16) 15.0% (12/80)  
   NOAC 0% (0/16) 2.5% (2/80)  
   None 100% (16/16) 82.5% (66/80)  
  Statin 25.0% (4/16) 20.3% (16/79) 0.738
Systolic blood pressure, mm Hg 162 (130–182; n=16) 157 (135–171; n=77) 0.558
Diastolic blood pressure, mm Hg 79 (71–105; n=16) 79 (69–90; n=77) 0.562
Admission glucose, mmol/L 6.8 (5.7–8.4; n=15) 6.5 (5.9–7.6; n=77) 0.711
Admission INR 1.0 (1.0–1.1; n=16) 1.0 (1.0–1.1; n=77) 0.177
Admission Platelet count 265 (227–392; n=16) 201 (168–257; n=79) 0.001*
TOAST   0.029†
  Large‐artery atherosclerosis 0% (0) 8.8% (7/80)  
  Cardioembolic 18.8% (3/16) 43.8% (35/80)  
  Other pathogenesis 31.3% (5/16) 8.8% (7/80)  
  Unknown pathogenesis 50.0% (8/16) 38.8% (31/80)  
Symptom-onset to admission (witnessed symptom onset only, min) 106 (77–163; n=9) 108 (67–200; n=48) 0.896
Symptom-onset to admission (including last-seen-well, min) 162 (101–307; n=15) 152 (74–249) 0.392
Initial modality for imaging diagnosis   0.788
  CT 43.8% (7/16) 48.8% (39/80)  
  MRI 56.3% (9/16) 51.2% (41/80)  
Intravenous tPA bridging 31.3% (5/16) 40.0% (32/80) 0.584
Intracranial occlusion site   Matched
  Intracranial ICA or carotid T 12.5% (2/16) 12.5% (10/80)  
  M1 43.8% (7/16) 43.8% (35/80)  
  M2/M3/A1 37.5% (6/16) 37.5% (30/80)  
  Posterior circulation 6.3% (1/16) 6.3% (5/80)  
(Continued )
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differentiating atherosclerotic changes from material-induced 
spasm. The majority of reocclusions occurred in patients with 
residual embolic fragments at the thrombectomy site that had 
not been recognized on the final control run, either because 
the distal flow was not hindered or because the image settings 
were not optimal (overlapping branches, contrast too dark, 
large field of view). These residual fragments may have acted 
as kernels to which the higher concentration of circulating 
platelets may have adhered to, explaining why a new occlu-
sive thrombus may have formed in the same location.
High preprocedural mean platelet volume has been shown 
to promote restenosis after carotid stenting, which may pos-
sibly be hindered by intensifying antiplatelet therapy.17 
Similarly, patients with elevated platelet counts on admission 
undergoing thrombectomy might benefit from more aggres-
sive antiaggregation therapy because it does not necessarily 
increase the risk of intracranial hemorrhage or impact clinical 
outcome negatively in those who benefit from carotid stenting 
despite having received intravenous recombinant tissue-type 
plasminogen activator.18 Aspirin may not be sufficient, how-
ever, since 4 of 16 (25%) with early reocclusion were under 
such therapy at the time of admission in our cohort. However, 
although sustained reperfusion is of utmost importance, an 
overly aggressive antiplatelet might be counterproductive by 
theoretically increasing the risk of intracranial hemorrhage. 
Future studies are needed to answer this question.
To avoid missing residual debris or an underlying plaque 
that could lead to early reocclusion, careful reinspection of 
the original occlusion site on the past angiographic run is ad-
vised. Adjustment of contrast/windowing levels, pixel shift, 
and zoom in the region of interest, followed by another run 
in different projections or 10 minutes later may be neces-
sary, especially after tentative corrective measures have been 
applied, such as spasmolytic therapy, intensified antiplatelet 
medication, or PTA/stenting. Prompt identification of early 
recocclusion may lead to timely repeated thrombectomy and 
thus improve outcome.19
The rates of early (24–48 hours) and late (90 days) good 
functional outcome and the rate of repeated thrombectomy 
were low in our series, stressing the importance of identifying 
reocclusion as early as possible to be able to offer a timely 
rescue therapy and improve clinical outcome.11 Indeed, 
effective repeated thrombectomy for recurrent large vessel 
occlusions has been reported in 2% of cases in a registry of 
697 patients.19 In this study of comparable size, the overall 
reocclusion rate was similar to ours but lower in the 24- to 
48-hour range, which may relate to the low number of M2 
occlusions in their collective (n=4). Moreover, the dominant 
Tandem occlusion (cervical occlusion or >90% stenosis) 6.3% (1/16) 15.0% (12/80) 0.688
Underlying cervical dissection (on admission) 6.3% (1/16) 2.5% (2/80) 0.425
Intervention
  General anesthesia 56.3% (9/16) 66.3% (53/85) 0.568
  No. of maneuvers 1 (1–4) 1 (1–2) 0.265
  Time from groin to TICI2b, min 43 (29–59) 36 (26–55) 0.284
  BGC 68.8% (11/16) 63.3% (50/80) 0.780
  Distal aspiration catheter 50.0% (8/16) 48.8% (39/80) >0.999
  Intracranial stenting 0% (0/16) 0% (0/80) …
  Extracranial stenting 6.3% (1/16) 13.8% (11/80) 0.684
  TICI3 56.3% (9/16) 56.3% (45/80) >0.999
  Residual thrombus not impeding distal flow 81.3% (13/16) 15.0% (12/80) <0.001*
Dual antiplatelet medication refers to aspirin+another antiplatelet drug (clopidogrel, prasugrel, etc). BGC indicates balloon-guiding catheter; CAD, coronary artery 
disease; CT, computed tomography; CVE, cerebrovascular event; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NOAC, novel oral 
anticoagulant (rivaroxaban, apixaban, etc); OAC, oral anticoagulant (coumarins); TICI, Thrombolysis in Cerebral Infarction; and tPA, tissue-type plasminogen activator.
*P<0.01, †P<0.05.
Table 3. Continued
 
Early (<48 Hours)  
Reocclusion (n=16)
No Early Reocclusion  
(1:5 Matching, n=80) P Value
Table 4. Logistic Regression With P<0.2 in Univariate Comparison  
(1:5 Occlusion Site Matching)
Variable Adjusted OR 95% CI P Value
TOAST (indicator: cardioembolic)   0.121
  Large‐artery atherosclerosis Did not converge
  Unknown pathogenesis 4.16 0.41–42.28 0.228
  Other pathogenesis 43.10 1.99–935.00 0.017*
Admission platelets 1.01 1.00–1.03 0.042*
Sex Variable excluded from model
Prestroke independence 0.05 0.00–1.01 0.055
Risk factor CAD Variable excluded from model
Admission INR Variable excluded from model
Risk factor arterial hypertension Variable excluded from model
Residual thrombus, vessel wall 
irregularities on control runs
58.94 4.94–703.16 0.001†
n=91; Nagelkerkes R2: 0.676. CAD indicates coronary artery disease; and 
OR, odds ratio.
*P<0.05, †P<0.01.
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underlying pathogenesis for reocclusion was cardioembolic 
stroke, which is probably more predictive of late than early 
reocclusion (median time between first and last procedures in 
their study: 18 days).
Despite the risk of vessel wall damage caused by material-
induced endothelial injury in animal models,20–22 the number 
of clot retrieval attempts with stent retrievers or the use of 
distal aspiration catheters was not associated with an increased 
risk of early reocclusion. This is in line with an immunohisto-
chemical analysis of retrieved thrombi in humans.23
This study had limitations. Despite our best efforts, in-
herent bias because of the retrospective and monocentric study 
design study was inevitable. Some successfully thrombecto-
mized patients had no arterial imaging on follow-up despite 
our institutional policy and were not included in the present 
analysis. A sensitivity analysis comparing the excluded and 
included patients revealed that those without arterial imaging 
on early follow-up were 4 years older on average, had 4× more 
sICH, twice the mortality rate, and twice as less good func-
tional outcomes at 90 days (Table II in the online-only Data 
Supplement). Therefore, although the prevalence of reocclu-
sion might be higher than what we report, we presume that 
this exclusion bias probably had little, if any, influence on 
our results. Another limitation worth mentioning is that there 
was no blinded core lab evaluation of the final angiographic 
results. Last, despite a 5:1 random matched occlusion site co-
hort, not all interventional DSA images of the complete col-
lective of mTICI 2b/3 patients were reviewed, which may 
have disclosed different or unexpected observations compared 
with the sampled population.
Conclusions
Early reocclusion within 48 hours after successful mechan-
ical thrombectomy is rare but associated with a poor clinical 
outcome. In our cohort, predictors were higher platelets on 
admission, prestroke functional dependency, missed residual 
thrombotic fragments or stenosis at the primary occlusion 
site, and stroke of undetermined or other specified patho-
genesis. Swift identification of these risk factors may allow 
prompt corrective measures towards sustained recanalization, 
including immediate repeated thrombectomy, which may 
improve outcome. The number of stent retriever passes, use of 
distal aspiration catheters, or other interventional parameters 
had no influence.
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